An Australian initiative that uses digital telecommunications to improve access to clinical trials in rural, regional and remote areas and deliver a more diverse pool of study participants for drug and medical device studies in a range of therapeutic areas is making headway.
Key Takeaways
-
The Australian Teletrials Program (ATP) is making good progress in setting up infrastructure needed to enable studies that make use of digital telecommunications to connect regional and rural clinical trial site clusters.
-
Teletrials are a subset of decentralized clinical trials and involve developing trial sites closer to the patient’s home, which can improve access and availability of health services closer to where people live.
-
As teletrials can enhance trial participant recruitment and retention by enabling access to rural, regional and remote areas, the program has drawn the interest of several companies, including Eli Lilly, Novo Nordisk and Sanofi.
-
The ATP covers a five year period (2021-2026) and is supported by a infrastructure-enabling grant of AUD 75.2m ($50.6 m)
The government-funded Australian Teletrials Program (ATP) has conducted more than 45 studies at its halfway mark, surpassing expectations, according to program director Kaye Hewson
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?